Ertugliflozin in participants with T2DM & Vascular disease

• Research type

  Research Study

• Full title

  Randomized, Double-Blind, Placebo-Controlled,Parallel- Group Study to assess cardiovascular outcomes following treatment with ertugliflozin (MK-8835/PF-04971729) in subjects with type 2 diabetes mellitus and established vascular disease, the VERTIS CV study

• IRAS ID

  141631

• Contact name

  Rory McCrimmon

• Contact email

  r.mccrimmon@dundee.ac.uk

• Sponsor organisation

  Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

• Eudract number

  2013-002518-11

• Clinicaltrials.gov Identifier

  NCT01986881

• REC name

  East of Scotland Research Ethics Service REC 2

• REC reference

  14/ES/0001

• Date of REC Opinion

  25 Feb 2014

• REC opinion

  Further Information Favourable Opinion